

Site open in Long Beach, CA for Retrotope Clinical Trial

FARA is supporting a Phase II clinical trial sponsored by Retrotope. The study drug RT001 may preserve mitochondrial function to cells in which lipid peroxidation compromises cellular energy production. Frataxin deficiency in mitochondria increases cellular susceptibility to lipid peroxidation, resulting in oxidative damage and cell death.

This study will involve five visits to a research clinic over a 12-month period. Participants will be reimbursed for reasonable travel expenses. Study sites are open in Long Beach and Los Angeles.

To qualify, you must:

- Have a documented diagnosis of Friedreich's ataxia
- Be 12 to 50 years old; ≥ 18 years old for the Long Beach site
- Be able to walk at least 25-feet within 1 minute, with or without an assistive device
- Not be actively enrolled in another clinical trial
- Not have participated in the previous RT001 trial

If you would like more information about your eligibility, please contact the study coordinator: **sarah@retrotope.com**